By activating PPARγ, asarinin inhibits the TGF-β canonical Smad pathway and the non-canonical AKT and MAPK pathways, thereby inhibiting the transition of fibroblasts to myofibroblasts, and thus lung fibrosis. The gene discussed is PPARG; the disease is pulmonary fibrosis.